Bart Reymen1, Angela van Baardwijk2, Rinus Wanders2, Jacques Borger2, Anne-Marie C Dingemans3, Gerben Bootsma4, Cordula Pitz5, Ragnar Lunde6, Wiel Geraedts7, Philippe Lambin2, Dirk De Ruysscher8. 1. Department of Radiation Oncology (MAASTRO Clinic), The Netherlands. Electronic address: bart.reymen@maastro.nl. 2. Department of Radiation Oncology (MAASTRO Clinic), The Netherlands. 3. Department of Pulmonology, University Medical Centre Maastricht, GROW-School for Oncology and Developmental Biology, The Netherlands. 4. Department of Pulmonology, Atrium Medical Centre, Heerlen, The Netherlands. 5. Department of Pulmonology, Laurentius Hospital, Roermond, The Netherlands. 6. Department of Pulmonology, St. Jansgasthuis, Weert, The Netherlands. 7. Department of Pulmonology, Orbis Medical Centre, Sittard, The Netherlands. 8. Department of Radiation Oncology (MAASTRO Clinic), The Netherlands; University Hospital Leuven/KU Leuven, Belgium.
Abstract
BACKGROUND: Non-small cell lung cancer (NSCLC) stage T4N0-1 or single nodal station IIIA-N2 are two stage III sub-groups for which the outcome of non-surgical therapy is not well known. We investigated the results of individualised isotoxic accelerated radiotherapy (INDAR) and chemotherapy in this setting. METHODS: Analysis of NSCLC patients included in 2 prospective trials (NCT00573040 and NCT00572325) stage T4N0-1 or IIIA-N2 with 1 pathologic nodal station, treated with chemo-radiotherapy (CRT) using INDAR with concurrent or sequential platinum-based chemotherapy. Overall survival (OS) was updated and calculated from date of diagnosis (Kaplan-Meier). Toxicity was scored following CTCAEv3.0. To allow comparison with other articles the subgroups were also analysed separately for toxicity, progression free and overall survival. RESULTS: 83 patients (42 T4N0-1 and 41 IIIA-N2) were identified: the median radiotherapy dose was 65Gy. Thirty-seven percent of patients received sequential CRT and 63% received concurrent CRT. At a median follow-up of 48 months the median OS for T4N0-1 patients was 34 months with 55% 2-year survival and 25% 5-year survival. For stage IIIA-N2 at a median follow-up of 50 months the median OS was 26 months with 2- and 5-year survival rates of 53% and 24%, respectively. CONCLUSION: Chemo-radiation using INDAR yields promising survival results in patients with single-station stage IIIA-N2 or T4N0-1 NSCLC.
BACKGROUND:Non-small cell lung cancer (NSCLC) stage T4N0-1 or single nodal station IIIA-N2 are two stage III sub-groups for which the outcome of non-surgical therapy is not well known. We investigated the results of individualised isotoxic accelerated radiotherapy (INDAR) and chemotherapy in this setting. METHODS: Analysis of NSCLCpatients included in 2 prospective trials (NCT00573040 and NCT00572325) stage T4N0-1 or IIIA-N2 with 1 pathologic nodal station, treated with chemo-radiotherapy (CRT) using INDAR with concurrent or sequential platinum-based chemotherapy. Overall survival (OS) was updated and calculated from date of diagnosis (Kaplan-Meier). Toxicity was scored following CTCAEv3.0. To allow comparison with other articles the subgroups were also analysed separately for toxicity, progression free and overall survival. RESULTS: 83 patients (42 T4N0-1 and 41 IIIA-N2) were identified: the median radiotherapy dose was 65Gy. Thirty-seven percent of patients received sequential CRT and 63% received concurrent CRT. At a median follow-up of 48 months the median OS for T4N0-1 patients was 34 months with 55% 2-year survival and 25% 5-year survival. For stage IIIA-N2 at a median follow-up of 50 months the median OS was 26 months with 2- and 5-year survival rates of 53% and 24%, respectively. CONCLUSION: Chemo-radiation using INDAR yields promising survival results in patients with single-station stage IIIA-N2 or T4N0-1 NSCLC.
Authors: Nika Guberina; Christoph Pöttgen; Martin Schuler; Maja Guberina; Georgios Stamatis; Till Plönes; Martin Metzenmacher; Dirk Theegarten; Thomas Gauler; Kaid Darwiche; Clemens Aigner; Wilfried E E Eberhardt; Martin Stuschke Journal: Radiat Oncol Date: 2022-07-16 Impact factor: 4.309
Authors: Tomas Skripcak; Claus Belka; Walter Bosch; Carsten Brink; Thomas Brunner; Volker Budach; Daniel Büttner; Jürgen Debus; Andre Dekker; Cai Grau; Sarah Gulliford; Coen Hurkmans; Uwe Just; Mechthild Krause; Philippe Lambin; Johannes A Langendijk; Rolf Lewensohn; Armin Lühr; Philippe Maingon; Michele Masucci; Maximilian Niyazi; Philip Poortmans; Monique Simon; Heinz Schmidberger; Emiliano Spezi; Martin Stuschke; Vincenzo Valentini; Marcel Verheij; Gillian Whitfield; Björn Zackrisson; Daniel Zips; Michael Baumann Journal: Radiother Oncol Date: 2014-10-28 Impact factor: 6.280